NCT02427620View on ClinicalTrials.gov

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

June 3, 2015

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Blastoid Variant Mantle Cell LymphomaMantle Cell LymphomaPleomorphic Variant Mantle Cell Lymphoma
Interventions
DRUG

Cyclophosphamide

Given IV

DRUG

Cytarabine

Given IV

DRUG

Dexamethasone

Given PO or IV

DRUG

Doxorubicin

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

DRUG

Ibrutinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Methotrexate

Given IV

BIOLOGICAL

Rituximab

Given IV

DRUG

Vincristine

Given IV

DRUG

Vincristine Sulfate

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER